Invitro assessment of polybutylcyanoacrylate nanoparticles on the a172 gliobalstoma cell line viability
Mahdieh sadat Taghavi
,1,* Hadi mohamadi
,2 Sabah naeimi
1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
2. Young researchers and elite club, Kermanshah branch, Islamic Azad university, Kermanshah, Iran
3. Parasitology department, Pasteur Institute of Iran, Tehran, Iran.
Brain targeting is one of the most challenging issue for the pharmaceutical research, as number of hydrophilic therapeutic agents such as antibiotics, anticancer drugs, are unable to cross blood brain barrier. in the past few years, a number of different approaches have been developed for drugs to overcome this barrier. the methods include direct injection into the brain, drug structural modifications and nanoparticulate carriers. polybutylcyanoacrylate (pbca), a biodegradable polymer, has been extensively investigated as a drug carrier in recent years. many studies have showed that pbca nanoparticles are able to transport therapeutic agents across the blood–brain barrier into the brain. the toxicity of nanoparticles is a dark point, especially for biomedical applications. in this study, we evaluated the toxicity of different concentrations of pbca nanoparticles on a172 glioblastoma cell line through mtt assay and annexine/pi flow cytometry.
Pbca nanoparticles were prepared by emulsion polymerization. the cytotoxicity effect of different concentrations of pbca nps(0, 3.1, 6.2, 12.5, 25, 50, 75 100, 150, and 200μg/ml) on a127 cells was determined by mtt assay. to determine the effects of pbca nanoparticles on apoptosis and/or necrosis, a172 cells were stained with annexin v and propidium iodide for flow cytometry analysis.
We evaluated the toxicity of different concentrations of pbca nanoparticles on a172 cell line. our mtt assay and flow cytometry data indicate that within a concentration of 100μg/ml, empty pbca nanoparticles imparts no cytotoxic effects on a172 cells.
A drug carrier device is suitable for in vivo applications only if it is nontoxice and biocompatible. in present study we evaluated the toxicity of different concentrations of pbca nanoparticles on a172 cell line and determined nontoxic concentrations of pbca nanoparticles for this cell line.
Pbca nanoparticles, a172, mtt assay, flow cytometry